Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the "Company") announced that at the 2025 European Society for Medical ...

AstraZeneca and Daiichi Sankyo's drug Enhertu has shown strong results in two pivotal studies in the early stage of a certain ...

ENHERTU Followed by THP Before Surgery Resulted in Pathologic Complete Response in 67% of Patients w/High-Risk HER2 Positive ...

Endocrine therapy typically slows cell cycle progression by reducing cyclin D1, which partners with CDK4/6 to promote cell ...

For patients with high-risk HER2-positive early breast cancer who have undergone neoadjuvant therapy, treatment with Enhertu (fam-trastuzumab deruxtecan-nxki) significantly improved invasive ...

AstraZeneca and Daiichi Sankyo’s star drug Enhertu has delivered a double knockout, showing its ability to stave off early ...

Pfizer's oncology portfolio has produced a second positive phase 3 trial in HER2-positive breast cancer in the span of about ...

In the intent-to-treat population, the median progression-free survival (PFS) was 8.77 months with giredestrant plus Afinitor ...

According to Boehringer, Hernexeos achieved a 77% objective response rate (OOR) in a cohort of previously untreated HER2+ ...

Findings from DESTINY-Breast11 showed T-DXd followed by THP demonstrated a statistically significant and clinically meaningful improvement in pCR rate vs ddAC-THP.

Learn about HER2+ breast cancer, its aggressive nature, and the latest treatments available in India. Explore the impact of ...

Zongertinib received FDA approval for HER2-mutant NSCLC, showing efficacy in first-line treatment with a 77% objective ...